AbbVie (ABBV) Stock Price, Quote, News & History | Benzinga

AbbVie Inc (ABBV) — Q1 FY26 Earnings Call Live coverage with Benzinga. Q1 FY26 Results EPS: $2.65 (est. $2.66) — inline Revenue: $15.00B (est. $14.73B) — inline Reported: 2026-04-29 Recent Quarters Q4 FY25 (2026-02-04): EPS $2.71 vs est $2.66 · Rev $16.62B vs est $16.39B Q3 FY25 (2025-10-31): EPS $1.86 vs est $1.78 · Rev $15.78B vs est $15.59B Q2 FY25 (2025-07-31): EPS $2.97 vs est $2.90 · Rev $15.42B vs est $15.05B Q1 FY25 (2025-04-25): EPS $2.46 vs est $2.38 · Rev $13.34B vs est $12.92B About AbbVie Inc AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio. https://www.abbvie.com · North Chicago, IL, USA · 57,000 employees Follow Benzinga X: https://x.com/Benzinga Facebook: https://www.facebook.com/Benzinga/ Instagram: https://www.instagram.com/benzinga/ ⚠️ Disclaimer: Investing in financial markets carries risk, and there are no guaranteed returns. All information is for educational purposes only and should not be taken as financial advice. Always do your own research and speak with a qualified financial advisor before making investment decisions. Only invest what you can afford to lose. Past performance does not guarantee future outcomes. #earnings #ABBV #stocks #benzinga